Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PAPalisade Bio, Inc. logo

Palisade Bio, Inc. (PALI)

NASDAQ Capital Market · Currency in USD
$1.33 ▼ -0.02 (-1.48%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.30 ▼ -0.03 (-2.26%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.35
Open
$1.36
Day's Range
$1.28 – $1.37
52 Week Range
$1.28 – $2.86
Volume
1,153,855
Avg. Volume
2,994,478
Market Cap
$231.78M
Beta (5Y Monthly)
1.62
PE Ratio (TTM)
--
EPS (TTM)
-$0.15
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$4.50

Profile: Palisade Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
14
CEO
J. D. Finley

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.06 · Revenue est. $465.30K
DateEst.Actual
Aug 10, 2026-$0.05-$0.05Beat
May 12, 2026-$0.04-$0.05Miss
Mar 23, 2026-$0.02-$0.04Miss
Nov 10, 2025-$0.32-$0.38Miss
Aug 11, 2025-$0.48-$0.58Miss
May 12, 2025-$0.84-$0.47Beat

Analyst view

Consensus price target
$4.50 ▲ +238.3%
Range $2.00 – $7.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on PALI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.